Han Songtao, Wang Senyu, Li Yuxia, He YuJiao, Ma Jing, Feng Yangchun
Clinical Laboratory CenterHospital of Traditional Chinese Medicine, Affiliated to Xinjiang Medical University, Urumqi, 830011, China.
Xinjiang Uygur Autonomous Region Radiotherapy Clinical Research and Training Center, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830011, China.
Discov Oncol. 2024 Sep 20;15(1):468. doi: 10.1007/s12672-024-01291-8.
Ferroptosis can be used as a powerful predictor of cancer prognosis. HPV persistent infection is the main cause of cervical cancer, so it is very important to improve the prognosis of patients. Therefore, it is necessary to explore the value of HPV-ferroptosis related genes as prognostic biomarkers of cervical cancer patients.
In this study, differentially expressed HPV-ferroptosis related genes were obtained from GSE7410, HPV gene set crossed with iron death genes. Five HPV-ferroptosis related genes with prognostic features were finally identified: CYBB, VEGFA, CKB, EFNA1 and HELLS. Multifactorial Cox regression was applied to establish and validate the prognostic model, and drug susceptibility and immune infiltration analyses were also performed.
The prognostic model was validated in the training set (TCGA) and validation set (GSE44001). Kaplan-Meier curves reveal significant differences in overall survival (OS) between high-risk and low-risk groups. Receiver operating characteristic (ROC) curve reflects the stability and accuracy of the prognostic model established in this study. In terms of immune function, T cell costimulation was better in the low-risk group than in the high-risk group (P < 0.01). The therapeutic effects of cisplatin, paclitaxel, docetaxel and cyclophosphamide, commonly used chemotherapy drugs for cervical cancer, are better in the high-risk group than in the low-risk group (P < 0.001).
HPV-ferroptosis related gene prognostic model not only has good stability and accuracy in predicting the prognosis of cervical cancer patients, but also has certain guiding value for clinicians in terms of drug sensitivity and immune microenvironment.
铁死亡可作为癌症预后的有力预测指标。人乳头瘤病毒（HPV）持续感染是宫颈癌的主要病因，因此改善患者预后非常重要。所以，有必要探索HPV-铁死亡相关基因作为宫颈癌患者预后生物标志物的价值。
在本研究中，从GSE7410（HPV基因集与铁死亡基因交叉）中获取差异表达的HPV-铁死亡相关基因。最终确定了五个具有预后特征的HPV-铁死亡相关基因：CYBB、VEGFA、CKB、EFNA1和HELLS。应用多因素Cox回归建立并验证预后模型，同时进行药物敏感性和免疫浸润分析。
该预后模型在训练集（TCGA）和验证集（GSE44001）中得到验证。Kaplan-Meier曲线显示高危组和低危组之间总生存期（OS）存在显著差异。受试者工作特征（ROC）曲线反映了本研究建立的预后模型的稳定性和准确性。在免疫功能方面，低危组的T细胞共刺激优于高危组（P < 0.01）。宫颈癌常用化疗药物顺铂、紫杉醇、多西他赛和环磷酰胺在高危组的治疗效果优于低危组（P < 0.001）。
HPV-铁死亡相关基因预后模型不仅在预测宫颈癌患者预后方面具有良好的稳定性和准确性，而且在药物敏感性和免疫微环境方面对临床医生具有一定的指导价值。
